Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ramosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.83 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.83 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.83 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.83 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.83 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.83 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.83 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.83 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.83 |
| ▸ | HTR2B | P41595 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ramosetron SCHEMBL447023 | 1.00 | HTR3A (0.83) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL30318895 | 1.00 | HTR3A (0.83) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL16701 | 0.99 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL13531398 | 0.99 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL9048395 | 0.99 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL2021739 | 0.99 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL29395241 | 0.99 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL9052272 | 0.93 | HTR3A (0.75) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL9048659 | 0.93 | HTR3A (0.75) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL8544326 | 0.92 | HTR3A (0.98) | HTR3AADRA2AADRA2BHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222003-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-07-10 | — | — | US | disclosed |
| CN-117794544-A | Pharmaceutical composition for treating solid tumor | 卫材R&D管理有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20120258164-A1 | TRANSDERMAL GRANISETRON | STRAKAN INTERNATIONAL LIMITED | 2012-10-11 | — | — | US | disclosed |
| US-7652052-B2 | Process for producing ramosetron or its salt | ASTELLAS PHARMA INC. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20100008974-A1 | TRANSDERMAL GRANISETRON | STRAKAN INTERNATIONAL LIMITED | 2010-01-14 | — | — | US | disclosed |
| US-7608282-B2 | Transdermal granisetron | STRAKAN INTERNATIONAL LIMITED (BM) | 2009-10-27 | — | — | US | disclosed |
| US-20090069570-A1 | Novel Process for Producing Ramosetron or Its Salt | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-1870408-A1 | NOVEL PROCESS FOR PRODUCING RAMOSETRON OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-12-26 | — | — | EP | disclosed |
| EP-1589956-B1 | TRANSDERMAL GRANISETRON | STRAKAN INT LTD (BM) | 2007-08-01 | — | — | EP | disclosed |
| US-20060177493-A1 | Transdermal granisetron | STRAKAN LIMITED (GB) | 2006-08-10 | — | — | US | disclosed |
| EP-0745382-B1 | INTRAORALLY SOLUBLE COMPRESSED MOLDING AND PROCESS FOR PRODUCING THE SAME | YAMANOUCHI PHARMA CO LTD (JP) | 2003-11-12 | — | — | EP | disclosed |
| EP-0781561-B1 | NOVEL MEDICINAL USE OF 5HT 3 ANTAGONIST | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-0651997-B1 | INTRABUCCALLY DISINTEGRATING PREPARATION AND PRODUCTION THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 1998-10-28 | — | — | EP | disclosed |
| EP-0745382-A1 | INTRAORALLY SOLUBLE COMPRESSED MOLDING AND PROCESS FOR PRODUCING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-04 | — | — | EP | disclosed |
| US-5576014-A | MIXTURE OF SACCARIDE GRANULES HAVING LOW MOLDABILITY AND HIGH MOLDABILITY | YAMANOUCHI PHARMACEUTICAL CO., LTD (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0682942-A1 | NOVEL, PERCUTANEOUSLY ABSORBABLE PREPARATION | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-11-22 | — | — | EP | disclosed |
| US-5466464-A | Sugars such as lactose and/or mannitol and agar | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-11-14 | — | — | US | disclosed |
| EP-0651997-A1 | INTRABUCCALLY DISINTEGRATING PREPARATION AND PRODUCTION THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069570-A1 | Novel Process for Producing Ramosetron or Its Salt | SI, VIP, HTR1D | HTR3A 101/4885HTR3E 195/4885HTR3B 256/4885 |
| US-20250222003-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | HTR3C, HTR3D, HTR3A | HTR3A 3/4885HTR3E 7/4885HTR3B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.